灵北亮相第八届进博会 展示神经专科与神经罕见病领域创新成果

Core Viewpoint - The eighth China International Import Expo (CIIE) will be held from November 5 to 10, 2025, in Shanghai, where the global pharmaceutical company Lundbeck will showcase its innovative therapies for developmental epileptic encephalopathy (DEE) and share advancements in migraine preventive treatment, emphasizing its commitment to making innovative therapies accessible to more patients in China [1][3]. Group 1: Company Initiatives - Lundbeck's General Manager for China, Zhang Yifan, highlighted the CIIE as a significant platform for deepening local cooperation and promoting advancements in neuroscience, aiming to raise awareness of the urgent needs of rare disease patients and the importance of migraine preventive treatment [3][4]. - The company has invested 20% of its annual revenue (approximately 4 billion Danish Kroner) into research and development, with 90% of its R&D pipeline focused on rare neurological diseases and specialized neurological treatments [4][5]. - Lundbeck has served over 74 million patients with brain diseases in China over the past 15 years, significantly accelerating clinical research across 19 provinces in the last five years [5][6]. Group 2: Clinical Research and Innovations - Lundbeck's investigational drug, bexicaserin, for treating DEE has initiated global Phase III clinical trials in China, addressing a critical unmet clinical need in this rare group of neurodevelopmental diseases [6][7]. - Bexicaserin has shown broad and lasting anti-seizure effects and has received breakthrough therapy designation from both the FDA and China's CDE, marking it as a potential "best-in-class" treatment for DEE [7][8]. - The company aims to improve migraine treatment in China, where approximately 130 million people are affected, and has made significant progress with its targeted CGRP monoclonal antibody, eptinezumab, which has shown efficacy in recent Phase III trials [7][8].